Part,  Chapter, Paragraph

 1   II,     5.  2.  6|      countries (now around 200 mg/dL). The different roles of
 2   II,     5.  2.  6|         levels ranging from 70 mg/dL in very high risk patients
 3   II,     5.  2.  6|           risk patients to 160 mg/dL in very low risk subjects)
 4   II,     5.  4.  1| hyperglycaemia 11.1 mmol/l (200mg/dl) in a random sample or a
 5   II,     5.  4.  1|         sample 7.0 mmol/l (126 mg/dl) and /or a postprandial
 6   II,     5.  6.  6|      Health 87:1680-1682~Reynolds DL, Chambers LW, Badley EM,
 7   II,     5.  6.  6|         Weyand CM, Hicok KC, Conn DL, Goronzy JJ (1992): The
 8   II,     9.  3.  1|          a repeated level <300 ng/dl (or 10.4 nmol/L) of total
 9   II,     9.  3.  1|          case the cut off is 5 ng/dl (50 pg/ml)(0.17 nmol/L).~ ~
10   II,     9.  3.  1|        EAU) - a cut off of 230 ng/dL (8 nmol/L) of total testosterone
11   II,     9.  3.  1|           serum level is > 346 ng/dL (12 nmol/L) ART is not necessary,
12   II,     9.  3.  1|        are between 230 and 346 ng/dL ART is optional and should
13  III,    10.  2.  1|     Metabolism 50:330-338.~ ~Katz DL, O’Connell M, Yeh MC, Nawaz
14  III,    10.  2.  2|      countries (now around 200 mg/dL). A 10% increase in plasma
15  III,    10.  2.  2|          3-4 mmol/l (~ 115-155 mg/dl).~ ~Various studies have
16  III,    10.  2.  2|          below 5 mmol/l (~ 190 mg/dl). High Density Lipoprotein (
17  III,    10.  2.  2|       than 1.2 mmol/l (~ 40-45 mg/dl) is considered a marker
18  III,    10.  2.  2|         levels ranging from 70 mg/dL in very high risk patients
19  III,    10.  2.  2|           risk patients to 160 mg/dL in very low risk subjects)
20  III,    10.  2.  4|    available at: htt ~ ~Ellsworth DL, O’Donnell CJ (2004): Emerging